← Back to Clinical Trials
Recruiting NCT05840575

NCT05840575 Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05840575
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition Chemotherapy-Related Cognitive Impairment
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2022-03-01
Primary Completion 2027-03-01

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 29 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2022-03-01 with a primary completion date of 2027-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function. The aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.

Eligibility Criteria

Inclusion Criteria: * Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet. * At the age of 7-29 years at diagnosis * Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin). Exclusion Criteria: * Unable to speak and understand Danish * Severe intellectual disability or mental health disorder that hinders participation * Brain metastases, * Terminal illness * Have had a previous chemotherapy or radiotherapy treatment

Contact & Investigator

Central Contact

Lisa L Hjalgrim, PhD, MD

✉ lisa.lyngsie.hjalgrim@regionh.dk

📞 +4535450962

Frequently Asked Questions

Who can join the NCT05840575 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 29 Years, studying Chemotherapy-Related Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05840575 currently recruiting?

Yes, NCT05840575 is actively recruiting participants. Contact the research team at lisa.lyngsie.hjalgrim@regionh.dk for enrollment information.

Where is the NCT05840575 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT05840575 clinical trial?

NCT05840575 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology